📉 Live Chart
Interactive · powered by TradingView
📊 marketbrief Score For reference
Our own score derived from public financial data, ranked against sector peers. Updated daily.
2.4
/ 5.0
Underweight
Grade C+, ranked against 60 peers in the Healthcare sector.
Valuation가치
D
Growth성장
C
Profitability수익성
C-
Momentum모멘텀
A
※ This score is informational only and not investment advice. See the methodology page for the formula. Methodology →
✍️ marketbrief View
Merck earns an A only on momentum, while valuation (D), profitability (C-), and growth (C) all lag, leaving its overall score at just 2.4 (C+). A P/E of 120.3x likely reflects market expectations that earnings are bottoming out amid patent-cliff concerns for key oncology drugs like Keytruda.
A 2.23% dividend yield is solid, but the key variable going forward is whether the drug pipeline can actually offset the patent cliff. Investors should distinguish whether the recent 77.5% rally reflects genuine fundamental improvement or simply a bounce off depressed expectations.
Key Stats
As of last close
Market Cap
$367.1B
PER
120.0
Dividend Yield
2.30%
52-Week High
$156.92
52-Week Low
$77.69
1-Year Return
+89.4%